Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis

European Journal of Haematology

Volumn 72, Issue 1, 2004, Pages 45-51

  Galimberti, S ^a   Guerrini, F ^a   Carulli, G ^a   Fazzi, R ^a   Palumbo, G A ^b   Morabito, F ^c   Petrini, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c Bone Marrow Transplant Unit   (Italy)

Author keywords

Acute myeloid leukemia; MDR1; Pgp; Real time polymerase chain reaction; Wilms' tumor gene

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WILM TUMOR GENE;

ADULT; BASE SEQUENCE; BONE MARROW CELLS; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; GENES, WILMS TUMOR; HUMANS; KIDNEY NEOPLASMS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, MESSENGER; TREATMENT OUTCOME; WILMS TUMOR; WT1 PROTEINS;

EID: 0742321800     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0902-4441.2003.00185.x     Document Type: Article

References (31)

1. HARRINGTON MA, KONICEK B, SONG A, XIA XL, FREDERICKS WJ, RAUSCHER FJ III. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 1993;28:21271-21275.
2. GOODYER P, DEHBI M, TORBAN E, BRUENING W, PELLETIER J. Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, WT1. Oncogene 1995;10:1125-1129.
3. HEWITT SM, HAMADA S, MCDONNELL TJ, RAUSCHER FJ III, SAUNDERS GF. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene: WT1. Cancer Res 1995;55:5386-5389.
4. HOSEN N, SONODA Y, QJI Y, et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 2002;2:409-420.
5. SEKIYA M, ADACHI M, HINODA Y, IMAI K, YACHI A. Downregulation of Wilms' tumor gene (WT1) during myelomonocytic differentiation in HL60 cells. Blood 1994;83:1876-1882.
6. PHELAN SA, LINDBERG C, CALL KM. Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. Cell Growth Differ 1994;5:677-686.
7. CHEN Z. The possible role and application of WT1 in human leukemia. Int J Hematol 2001;73:39-46.
8. KARAKAS T, MIETHING CC, MAURER U, WEIDMANN E, ACKERMANN H, HOELZER D, BERGMANN L. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Leukemia 2002;16:846-854.
9. SCHMID D, HEINZE G, LINNERTH B, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11:639-643.
10. BERGMANN L, MIETHING C, MAURER U, BRIEGER J, KARAKAS T, WEIDMANN E, HOELZER D. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90:1217-1225.
11. CILLONI D, GOTTARDI E, DE MICHELI D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16:2115-2121.
12. OGAWA H, TAMAKI H, IKEGAME K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003;101: 1698-1704.
13. MCCOY C, MCGEE SB, CORNWELL MM. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter. Cell Growth Differ 1999;10:377-386.
14. JURANKA P, ZASTAWNY R, LING V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989;3:2582-2585.
15. ZHOU DC, MARIE JP, SUBERVILLE AM, ZITTOUN R. Relevance of MDR1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992;6:879-885.
16. NUSSLER V, PELKA-FLEISCHER R, ZWIERZINA H, et al. P-glycoprotein expression in patients with acute leukemia-clinical relevance. Leukemia 1996;10 (Suppl. 3):S23-S31.
17. MARIE JP, LEGRAND O. MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol 1999;457:1-9.
18. WUCHTER C, LEONID K, RUPPERT V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000;85:711-721.
19. VAN DEN HEUVEL-EIBRINK MM, WIEMER EA, DE BOEVERE MJ, VAN DER HOLT B, VOSSEBELD PJ, PIETERS R, SONNEVELD P. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloia leukemia. Blood 2001;97:3605-3611.
20. BENNET JM, CATOVSKY D, DANIEL MT, FLAUDRING G, GRALNICK HR, SULTAN C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French, American-British Cooperative Group. Ann Intern Med 1985;103:620-625.
21. MICHIELI M, DAMIANI D, ERMACORA A, MASOLINI P, RASPADORI D, VISANI G, SCHEPER RJ, BACCARANI M. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol 1999;104:328-335.
22. CONSOLI U, SANTONOCITO AM, STAGNO F, et al. Mulitdrug resistance mechanisms in chronic lymphocytic leukaemia. Br J Haematol 2002;116:774-780.
23. JIANG EZ, CHANG YJ, LEE JW, LEE WK, KIM JS, SOHN SK, LEE KB, SUH JS. Multi-drug resistance (MDR1) gene expression in de novo acute leukemia cells: correlations with CD surface markers and treatment outcome. J Korean Med Sci 1998;13:617-622.
24. FUJIMAKI S, FUNATO T, HARIGAE H, FUJIWARA J, KAMEOKA J, MEGURO K, KAKU M, SASAKI T. Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia. Clin Chem 2002;48:811-817.
25. JOHNSTONE RW, CRETNEY E, SMYTH MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999;93:1075-1085.
26. CHIN KV, TANAKA S, DARLINGTON G, PASTAN I, GOTTESMAN MM. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990;265:221-226.
27. CORNWELL MM, SMITH DE. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 1993;268:15347-15350.
28. ZASTAWNY RL, SALVINO R, CHEN J, BENCHIMOL S, LING V. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 1993;8:1529-1535.
29. GALIMBERTI S, MARCHETTI A, BUTTITTA F, CARNICELLI V, PELLEGRINI S, BEVILACQUA G, PETRINI M. Multidrug resistance related genes and p53 expression in human non small cell lung cancer. Anticancer Res 1998;18:2973-2976.
30. GAIGER A, SCHMID D, HEINZE G, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998;12:1886-1894.
31. ZOCHBAUER S, GSUR A, BRUNNER R, KYRLE PA, LECHNER K, PIRKER R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994;8:974-977.